PARP inhibitors in ovarian cancer.

@article{Ledermann2016PARPII,
  title={PARP inhibitors in ovarian cancer.},
  author={Jonathan A Ledermann},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2016},
  volume={27 Suppl 1},
  pages={i40-i44}
}
BACKGROUND Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy. Poly(ADP-ribose) polymerase (PARP) inhibitors target DNA repair and are specifically active in cells that have impaired repair of DNA by the homologous recombination (HR) pathway. Cells with mutated BRCA function have HR deficiency (HRD), which is also present in a significant proportion of non-BRCA-mutated ovarian cancer. DESIGN… CONTINUE READING